[英夫利昔单抗治疗难治性前部弥漫性巩膜炎]
[Treatment of refractory anterior diffuse scleritis with infliximab].
作者信息
Díaz-Valle D, Miguélez Sánchez R, Fernández Espartero M C, Pascual Allen D
机构信息
Unidad de Inflamación Ocular, Hospital General de Móstoles, Madrid, Spain.
出版信息
Arch Soc Esp Oftalmol. 2004 Aug;79(8):405-8. doi: 10.4321/s0365-66912004000800010.
CASE REPORT
A 48-year old woman diagnosed with rheumatoid arthritis 10 years previously, developed severe anterior scleritis in the right eye (RE) refractory to conventional treatment. The patient was treated with 3 intravenous doses of Infliximab achieving complete remission of the scleral inflammation within four weeks.
DISCUSSION
The use of Infliximab, a blocker of tumour necrosis factor (TNFalpha) could be an alternative approach to the management of refractory scleritis, but further long-term investigations would be necessary to evaluate their safety and efficacy.
病例报告
一名48岁女性，10年前被诊断为类风湿关节炎，右眼发生严重的前部巩膜炎，对传统治疗无效。该患者接受了3次英夫利昔单抗静脉注射治疗，四周内巩膜炎症完全缓解。
讨论
使用肿瘤坏死因子（TNFα）阻滞剂英夫利昔单抗可能是治疗难治性巩膜炎的一种替代方法，但需要进一步的长期研究来评估其安全性和有效性。
Zotero 插件